REVIVE Trial: Retrograde Delivery of Autologous Bone Marrow in Patients With Heart Failure.

ABSTRACT:

Unlabelled

Cell therapy is an evolving option for patients with end-stage heart failure and ongoing symptoms despite optimal medical therapy. Our goal was to evaluate retrograde bone marrow cell delivery in patients with either ischemic heart failure (IHF) or nonischemic heart failure (NIHF). This was a prospective randomized, multicenter, open-label study of the safety and feasibility of bone marrow aspirate concentrate (BMAC) infused retrograde into the coronary sinus. Sixty patients were stratified by IHF and NIHF and randomized to receive either BMAC infusion or control (standard heart failure care) in a 4:1 ratio. Accordingly, 24 subjects were randomized to the ischemic BMAC group and 6 to the ischemic control group. Similarly, 24 subjects were randomized to the nonischemic BM

SUBMITTER: Patel AN 

PROVIDER: S-EPMC4542877 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature